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Abstract
Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions
that predominantly involve the skin and mucous membranes. Both are rare, with TEN and SJS affecting approxi-
mately 1or 2/1,000,000 annually, and are considered medical emergencies as they are potentially fatal. They are
characterized by mucocutaneous tenderness and typically hemorrhagic erosions, erythema and more or less severe
epidermal detachment presenting as blisters and areas of denuded skin. Currently, TEN and SJS are considered to
be two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only by their extent
of skin detachment. Drugs are assumed or identified as the main cause of SJS/TEN in most cases, but Mycoplasma
pneumoniae and Herpes simplex virus infections are well documented causes alongside rare cases in which the
aetiology remains unknown. Several drugs are at “high” risk of inducing TEN/SJS including: Allopurinol, Trimetho-
prim-sulfamethoxazole and other sulfonamide-antibiotics, aminopenicillins, cephalosporins, quinolones, carbamaze-
pine, phenytoin, phenobarbital and NSAID’s of the oxicam-type. Genetic susceptibility to SJS and TEN is likely as
exemplified by the strong association observed in Han Chinese between a genetic marker, the human leukocyte
antigen HLA-B*1502, and SJS induced by carbamazepine. Diagnosis relies mainly on clinical signs together with the
histological analysis of a skin biopsy showing typical full-thickness epidermal necrolysis due to extensive keratino-
cyte apoptosis. Differential diagnosis includes linear IgA dermatosis and paraneoplastic pemphigus, pemphigus vul-
garis and bullous pemphigoid, acute generalized exanthematous pustulosis (AGEP), disseminated fixed bullous drug
eruption and staphyloccocal scalded skin syndrome (SSSS). Due to the high risk of mortality, management of
patients with SJS/TEN requires rapid diagnosis, evaluation of the prognosis using SCORTEN, identification and inter-
ruption of the culprit drug, specialized supportive care ideally in an intensive care unit, and consideration of immu-
nomodulating agents such as high-dose intravenous immunoglobulin therapy. SJS and TEN are severe and life-
threatening. The average reported mortality rate of SJS is 1-5%, and of TEN is 25-35%; it can be even higher in
elderly patients and those with a large surface area of epidermal detachment. More than 50% of patients surviving
TEN suffer from long-term sequelae of the disease.
Background, disease name and synonyms
Stevens-Johnson syndrome (SJS) was first described in
1922, as an acute mucocutaneous syndrome in two
young boys. The condition was characterized by severe
purulent conjunctivitis, severe stomatitis with extensive
mucosal necrosis, and purpuric macules. It became
known as SJS and was recognized as a severe mucocuta-
neous disease with a prolonged course and potentially
lethal outcome that is in most cases drug-induced, and
should be distinguished from erythema multiforme (EM)
majus. Recent clinical studies have shown that the term
‘EM majus’ should not be used to describe SJS as they
are distinct disorders [1-4].
In 1956, Alan Lyell described four patients with an
eruption resembling scalding of the skin which he called
toxic epidermal necrolysis or TEN [4]. It was only as
more patients with TEN were reported in the years fol-
lowing Lyell’s original publication, that it became clear
that TEN was drug induced, and that certain drugs such
as sulfonamides, pyrazolones, barbiturates, and antiepi-
leptics were the most frequent triggers of TEN. Increas-
ingly to date, SJS and TEN are considered to be two
ends of a spectrum of severe epidermolytic adverse cuta-
neous drug reactions, differing only by their extent of
skin detachment.
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SJS and TEN are rare diseases in absolute numbers with
an incidence of 1.89 cases of TEN per million inhabi-
tants per year reported for Western Germany and Berlin
in 1996 [5]. La Grenade et al report similar results, with
1.9 cases of TEN per million inhabitants per year based
on all cases reported to the FDA AERS database in the
USA [6]. Lower incidence rates were reported by Chan
et al in Singapore [7]. Certain infectious diseases may
have an impact on the incidence of TEN, and this is
clearly the case for HIV where the annual incidence is
approximately 1000-fold higher than in the general
population, with approximately 1 case per thousand per
year in the HIV-positive population ([8]. In a study of
HIV positive patients of the greater Paris area in the
late eighties and early nineties, 15 cases of SJS/TEN
were reported in patients with AIDS compared to 0.04
expected cases [9]. In another study only ten out of
50 cases of SJS/TEN in HIV patients could be clearly
attributed to the use of medications, whereas in the
other cases a cause could not be determined due to lack
of data of drug intake or details [10].
Regional differences in drug prescription, the genetic
background of patients (HLA, metabolizing enzymes),
the coexistence of cancer, or concomitant radiotherapy
[11,12], can have an impact on the incidence of SJS
and TEN.
To a lesser extent, other infections have occasionally
been reported as the sole cause. Mycoplasma pneumo-
niae infections are widely documented to cause SJS and
TEN without initial exposure to drugs [13-15]. Further-
more, Herpes simplex virus was recognized in several
cases of SJS, especially in children [16]. Single case
reports describe Lupus erythematodes [17] or reactiva-
tion of Herpes simplex under treatment with azithromy-
cine as potential causes of SJS [18]. The occurrence of
TEN in a patient with severe aplastic anaemia after allo-
geneic haematopoietic stem cell transplantation has also
been reported [19]. However there are still cases of SJS/
TEN without any obvious identifiable cause.
Clinical Features
Acute Phase
Initial symptoms of toxic epidermal necrolysis (TEN) and
Stevens Johnson Syndrome (SJS) can be unspecific and
include symptoms such as fever, stinging eyes and dis-
comfort upon swallowing. Typically, these symptoms pre-
cede cutaneous manifestations by a few days. Early sites
of cutaneous involvement are the presternal region of the
trunk and the face, but also the palms and soles. Involve-
ment (erythema and erosions) of the buccal, genital and/
or ocular mucosa occurs in more than 90% of patients,
and in some cases the respiratory and gastrointestinal
tracts are also affected [20,21]. Ocular involvement at the
onset of disease is frequent, and can range from acute
conjunctivitis, eyelid edema, erythema, crusts, and ocular
discharge, to conjunctival membrane or pseduomembrane
formation or corneal erosion, and, in severe cases, to
cicatrizing lesions, symblepharon, fornix foreshortening,
and corneal ulceration [22,23]. The severity of acute ocu-
lar manifestation is not however predictive of late compli-
cations [24]. The morphology of early skin lesions
includes erythematous and livid macules, which may or
may not be slightly infiltrated, and have a tendency to
rapid coalescence (Table 1). The above mentioned skin
signs associated with mucosal involvement are clear dan-
ger signs and warrant the initiation of rapid diagnostic
confirmation with immediate cryosections of a skin
biopsy. Histological examination including direct immu-
nofluorescence analysis of the skin biopsy is also impor-
tant in order to rule out differential diagnoses such as
autoimmune blistering diseases, bullous fixed drug erup-
tion, acute generalized exanthematic pustulosis, and due
to its rarity in adults, to a lower extend staphyloccocal
scalded skin syndrome.
In a second phase, large areas of epidermal detach-
ment develop. In the absence of epidermal detachment,
more detailed skin examination should be performed by
exerting tangential mechanical pressure on several
erythematous zones (Nikolsky sign). The Nikolsky sign
is positive if mechanical pressure induces epidermal
detachment, but is not specific for TEN or SJS, as it can
also be positive in, for example, autoimmune bullous
skin diseases.
The extent of skin involvement is a major prognostic
factor. It should be emphasized that only necrotic skin,
which is already detached (e.g. blisters, erosions) or
detachable skin (Nikolsky positive) should be included
in the evaluation of the extent of skin involvement. Bas-
tuji-Garin et al. proposed classifying patients into three
groups according to the degree of skin detachment
(Table 1, Figure 1) [1].
Late phase and sequelae
Sequelae are common features of late phase TEN.
According to the study of Magina et al [25] following
symptoms are found: hyper- and hypopigmentation of
the skin (62.5%), nail dystrophies (37.5%), and ocular
complications. According to a study of Yip et al. 50% of
patients with TEN develop late ocular complications
including, by order of decreasing frequency, severe dry
eyes (46% of cases), trichiasis (16%), symblepharon
(14%), distichiasis (14%), visual loss (5%), entropion
(5%), ankyloblepharon (2%), lagophthalmos (2%), and
corneal ulceration (2%) [24]. Hypertrophic scars are only
seen in very few patients [26]. Long-term complications
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present mucosal involvement in the acute phase, and
the mucosal sequelae involve mainly the oral and oeso-
phageal mucosa, and to a lesser extent lung and genital
mucosa [27]. In a small post SJS/TEN study seven out
of nine patients had either xerostomia or keratoconjunc-
tivitis or both, resembling Sjögren-like syndrome [28].
Additionally, another group reported a patient with
Sjögren-like pluriglandular exocrine insufficiency includ-
ing exocrine pancreatic impairment [29].
Etiology and pathogenesis
Genetic susceptibility
Genetic factors associated with drug hypersensitivity are a
complex issue that has been studied in different
populations and a variety of ethnic backgrounds. A unique
and strong association between HLA, drug hypersensitivity
and ethnic background was discovered by Chung et al.
who showed a strong association in Han Chinese between
the HLA-B*1502, SJS and carbamazepine [30]. This high
association with an odds ratio of 2504 led to further stu-
dies in a similar ethnical group of Hong Kong Han Chi-
nese with severe adverse reactions to antiepileptic drugs
[31]. Another study confirmed the susceptibility of indivi-
duals with HLA-B*1502 to carbamazepine in a Thai popu-
lation [32]. A smaller Indian based study however showed
only a weak correlation between HLA-B*1502 and carba-
mazepine induced severe drug allergy. A genetic correla-
tion could not however be shown in Japanese or
Europeans [33-35]. Indeed, in a large European study
(RegiSCAR), HLA-B genotyping was performed in patients
with severe cutaneous adverse reactions caused by the two
previously mentioned drugs (carbamazepine, allopurinol)
and another three high risk drugs (sulfamethoxazole,
lamotrigine, NSAID’s of oxicam-type). This RegiSCAR
study revealed that HLA-B*1502 is neither a marker for
carbamazepine, sulfamethoxazole, lamotrigine, or NSAID’s
of oxicam-type induced SJS/TEN nor a sufficient explana-
tion for the cause of the disease in Europeans [35,36]. This
leads to the conclusion that this genetic constellation
(HLA-B*1502) is not a population independent marker for
SJS/TEN in carbamazepine exposed individuals. Severe
cutaneous reactions in HLA-B*1502 subjects were not
only associated with the drug carbamazepine, but also, to
a lesser extent (lower odds ratio), with phenytoin and
lamotrigine [31].
A second strong association between HLA genotype
and SJS/TEN has been reported for allopurinol. Indeed,
100% of Han Chinese patients with a severe adverse
drug reaction to allopurinol were HLA-B*5801 positive
[37]. Subsequently, a strong association between SJS/
TEN and HLA-B*5801 was found in Japanese patients
[34], Thai patients [32], and also, to a lesser extent (55%
of cases), in patients of European origin [36].
Table 1 clinical features that distinguish sjs, sjs-ten overlap, and ten (adapted after 1)
Clinical entity SJS SJS-TEN overlap TEN
Primary lesions Dusky red lesions Dusky red lesions Poorly delineated erythematous plaques
Flat atypical targets Flat atypical targets Epidermal detachment
Dusky red lesions
Flat atypical targets
Distribution Isolated lesions Isolated lesions Isolated lesions (rare)
Confluence (+) on face and
trunk
Confluence (++) on face and
trunk
Confluence (+++) on face, trunk, and
elsewhere
Mucosal involvement Yes Yes Yes
Systemic symptoms Usually Always Always
Detachment (%body surface
area)
<10 10-30 >30
Figure 1 Pictural representation of SJS, SJS-TEN overlap and
TEN showing the surface of epidermal detachment (Adapted
from Fig 21.9 Bolognia and Bastuji-Garin S. et al. Arch Derm
129: 92, 1993)
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The pathogenesis of SJS/TEN is not fully understood
but is believed to be immune-mediated, as re-challen-
ging an individual with the same drug can result in
rapid recurrence of SJS/TEN [38,39]. The histopathology
of SJS/TEN lesions show that keratinocyte apoptosis fol-
lowed by necrosis is the pathogenic basis of the wide-
spread epidermal detachment observed in SJS/TEN. The
clinical, histopathological and immunological findings in
SJS/TEN support the currently prevalent concept, that
SJS and TEN are specific drug hypersensitivity reactions
in which cytotoxic T lymphocytes (CTL) play a role in
the initiation phase. Indeed, in the early phase of
disease, blister fluid contains mainly cytotoxic CD8+T
lymphocytes [40,41], suggesting that a major histocom-
patibility (MHC) class-I restricted drug presentation
leads to clonal expansion of CD8+ CTLs, and the subse-
quent - to date only incompletely understood - immune
reaction that causes SJS/TEN. These CD8+ T cells
express common cutaneous leukocyte antigen (CLA)
and are negative for CD45RA and CD28. Nassif et al.
were able to demonstrate that blister T cells from
patients exert drug specific cytototoxic activity against
both autologous B-lymphocyte cell lines and keratino-
cytes [42], and furthermore demonstrated that this cell-
mediated cytotoxicity was mediated by granzyme B. The
discrepancy between the paucity of the infiltration of
immune cells (including CTLs) in the skin of patients
with SJS/TEN and the overwhelming keratinocyte apop-
tosis has however lead to the search for cytotoxic pro-
teins and/or cytokines that may “amplify” the extent of
keratinocyte apoptosis that CTLs alone could induce
upon cell-cell contact. To date, the strongest evidence
suggests a key contribution of the cytotoxic molecules
FasL and granulysin as molecules responsible for the
disseminated keratinocyte apoptosis in SJS/TEN [43,44].
The role of the membrane form of the death ligand
FasL and its cognate death receptor Fas in the signalling
that triggers keratinocyte apoptosis is supported by
research performed using an ex-vivo experimental set
up with TEN lesional skin biopsy cryostat section over-
lays with Fas-expressing lymphoid target cells [44].
However, the functional relevance of up-regulated kera-
tinocyte membrane FasL, and thus its ability to induce
keratinocyte cell death, has been questioned by some as
the above ex-vivo demonstration of the lytic ability of
keratinocyte FasL in TEN was limited in its effect on
lymphoid target cells and not demonstrated with kerati-
nocytes as target cells. It is well known that primary
keratinocytes are sensitive to the cytolytic effect of FasL
in vitro, and this sensitivity can be further enhanced by
interferon gamma, a cytokine known to be present in
the skin during TEN [45-47]. However, it is still not
fully understood what causes the up-regulation of FasL/
Fas on keratinocytes, and how the immune system,
including T cells found in blister fluid at the onset of
disease may regulate this.
The role of soluble FasL (sFasL) in SJS/TEN remains
controversial. It appears clear now that increased levels
of sFasL can be found in the serum of patients with SJS/
TEN, and levels of sFasL are consistently elevated when
analysis is performed preceding skin detachment [48].
Soluble FasL as opoposed to membrane-bound FasL is,
however, very poorly cytolytic, and it is therefore unli-
kely to be a cause of keratinocyte apoptosis in TEN
[49]. Nevertheless, one study showed that sera of SJS/
TEN were able to induce abundant keratinocyte apopto-
sis and furthermore that peripheral blood monuclear
cells of patients stimulated by the causative drug
excreted high levels of sFasL [50], but it should be
noted that sera can contain small membrane vesicles
with membarne bound FasL that can account for the
observed activity.
Gene expression analysis of blister fluid cells, and ana-
lysis of blister fluid from patients with SJS/TEN has also
recently identified secretory granulysin (a cationic cyto-
lytic protein secreted by CTL’s, NK cells and NKT cells)
as a key molecule responsible for the induction of kera-
tinocyte death in TEN [43]. Blister fluid cells express
high levels of granulysin mRNA, the protein is found in
increased concentrations in blister fluid, and most
importantly, recombinant granulysin mimicks features of
SJS/TEN when injected intradermally in mice. The find-
ing that elevated serum granulysin levels apparently dis-
criminate between serious and non-blistering adverse
drug reactions, serum granulysin levels being normal in
the latter, lends further support an important role of
granulysin in SJS/TEN [51].
In conclusion, and based on our knowledge to date,
CD8 T-cells as well as the cytolytic molecules FasL and
granulysin are key players in the pathogenesis of SJS/
TEN. How a culprit drug in a given patient who will
develop SJS/TEN regulates the function of these key
players is the subject of ongoing research.
Drugs
Drug exposure and a resulting hypersensitivity reaction
is the cause of the very large majority of cases of SJS/
TEN. In absolute case numbers, allopurinol is the most
common cause of SJS/TEN in Europe and Israel [52],
and mostly in patients receiving daily doses of at least
200 mg.
In a case control study of patients hospitalized for SJS/
TEN in selected hospitals in France, Germany, Italy and
Portugal between 1989 and 1993, Roujeau et al. reported
that the following drugs are at increased risk of inducing
SJS/TEN when used over a short period of time: trime-
troprim-sulfamethoxazole and other sulfonamide-
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and chlormezanone. Among drugs usually taken for
longer periods of time (carbamazepine, phenytoin, phe-
nobarbital, valproic acid, non-steroidal antinflammatory
drugs of the oxicam-type, allopurinol and corticoster-
oids), the highest risk of induction of SJS/TEN occurs
during the first 2 months of treatment with a sharp
drop of incidence thereafter [8]. However, although
these drugs have a high relative risk compared to other
drugs, the actual risk remained low with 5 cases or less
per million users per week. A similar population was
studied between 1997 and 2001 by Mockenhaupt et al.
in a multinational case-control study in Europe covering
more than 100 million inhabitants in which special
attention was given to newly marketed drugs [53]. This
study identified nevirapine, lamotrigine, and sertraline,
as drugs with a significantly increased risk of inducing
SJS/TEN. Older drugs identified as having a high risk of
inducing SJS/TEN were sulfamethoxazol/trimethoprim
(SMX/TMP), sulfonamides (sulfasalazine, sulfadiazine,
sulfadoxine, sulfafurazole), allopurinol, carbamazepine,
phenytoin, phenobarbital, and NSAID’s of the oxicam-
type (meloxicam, piroxicam, tenoxicam). However the
incidence of SJS/TEN under treatment with valproic
acid is confounded by the concomitant use of other
drugs, such as lamotrigine [5]. Mockenhaupt et al. were
able to show that almost all cases of SJS/TEN developed
within 63 days of starting use of antiepileptic drugs, and
that the risk of developing SJS/TEN per 10 000 new
users was significantly increased for carbamazepine
(1.4 cases per 10 000 users), lamotrigine (2.5), phenobar-
bital (8.1) and phenytoine (8.3). The incidence for val-
proic acid was low compared to other antiepileptic
drugs with 0.4 cases per 10 000 users [54]. Furthermore,
studies in different populations indicate that the risk of
developing SJS/TEN is highest when the drug has been
recently initiated, and subsequently declines within 8
weeks or more of administration [5,55]. Interestingly the
long term use of glucocorticosteroids for a variety of
diseases does not change the incidence of the occur-
rence of SJS/TEN for the incriminated drugs, but it
appears that glucocorticoids lengthen the interval
between the beginning of the intake of the drug and
onset of SJS/TEN [56]. A recent survey of TEN in chil-
dren identified similar drugs to those in adults, as well
as a possibly increased susceptibility to acetaminophen
(paracetamol) [57].
Photo-induced TEN or SJS are only reported in very rare
cases. Case reports exist for hydroxchloroquine [58],
naproxene [59] and clobazam [60]. An often addressed
issue is the induction of TEN or SJS after vaccination. The
vaccine adverse event reporting system concludes that
despite the plausibility of a relationship between vaccination
and SJS/TEN, the very small number of reports compared
to the large amount of vaccinations and the benefits of vac-
cinations outweighs the potential risk of SJS/TEN [61].
Diagnosis and diagnostic methods
The diagnosis relies on the one hand on clinical symp-
toms and on the other hand on histological features.
Typical clinical signs initially include areas of erythema-
tous and livid macules on the skin, on which a positive
Nikolsky sign can be induced by mechanical pressure on
the skin, followed within minutes to hours by the onset
of epidermal detachment characterized by the develop-
ment of blisters. It should be noted, however, that the
Nikolsky sign is not specific for SJS/TEN. Mucosal,
including ocular, involvement develops shortly before or
simultaneously with skin signs in almost all cases. To
distinguish SJS, SJS-TEN and TEN the surface area of
the detachment is the main discriminating factor (Figure
1). Histological work up of immediate cryosections or
conventional formalin-fixed sections of the skin reveal-
ing wide spread necrotic epidermis involving all layers
confirms the diagnosis. In order to rule out autoimmune
blistering diseases, direct immune fluorescence staining
should be additionally performed and no immunoglobu-
lin and/or complement deposition in the epidermis and/
or the epidermal-dermal zone should be detected.
Differential diagnosis
Major differential diagnosis of SJS/TEN are autoimmune
blistering diseases, including linear IgA dermatosis and
paraneoplastic pemphigus but also pemphigus vulgaris
and bullous pemphigoid, acute generalized exanthema-
tous pustulosis (AGEP), disseminated fixed bullous drug
eruption and staphyloccocal scalded skin syndrome
(SSSS). SSSS was one of the most important differential
diagnoses in the past, but the incidence is currently very
low with 0.09 and 0.13 cases per one million inhabitants
per year [54].
Management and Therapy
Treatment in acute stage
Management in the acute stage involves sequentially
evaluating the severity and prognosis of disease, prompt
identification and withdrawal of the culprit drug(s),
rapidly initiating supportive care in an appropriate set-
ting, and eventual “specific” drug therapy as described in
detail below.
Rapid evaluation of severity and prognosis
As soon as the diagnosis of SJS or TEN has been estab-
lished, the severity and prognosis of the disease should
be determined so as to define the appropriate medical
setting for further management. In order to evaluate
prognosis in patients with SJS/TEN, the validated
SCORTEN disease severity scoring system can be used
(see section devoted to prognosis and Table 2). Patients
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ged in an intensive care unit if possible.
Prompt withdrawal of culprit drug(s)
Prompt withdrawal of causative drugs should be a prior-
ity when blisters or erosions appear in the course of a
drug eruption. Garcia-Doval et al. have shown that the
earlier the causative drug is withdrawn, the better the
prognosis, and that patients exposed to causative drugs
with long half-lives have an increased risk of dying [62].
In order to identify the culprit drug(s) it is important to
consider the chronology of administration of the drug
and the reported ability of the drug to induce SJS/TEN.
The chronology of administration of a culprit drug, or
time between first administration and development of
SJS/TEN, is between 1 and 4 weeks in the majority of
cases. The reported ability or likelihood of a drug be the
cause of SJS/TEN can be found in Pubmed/Medline or
other appropriate sources such as the Litt’s drug erup-
tion reference manual [63].
Supportive Care
SJS/TEN is a life threatening condition and therefore
supportive care is an essential part of the therapeutic
approach [64]. A multicenter study conducted in the
USA [65], and including 15 regional burn centers with
199 admitted patients, showed that survival rate - inde-
pendent of the severity of disease (APACHE-score and
TBSA = Total body surface area) - was significantly
higher in patients who were transferred to a burn unit
within 7 days after disease-onset compared with patients
admitted after 7 days (29.8% vs 51.4% (p < 0.05)). This
positive association of early referral and survival has
been confirmed in other studies [27,66].
A single center retrospective study on the outcome of
patients after admission to a burn center identified sep-
sis at the time of admission as the most important nega-
tive prognostic factor, followed by age, and to a lesser
extent the percentage of total body surface area
involved. Co-morbidities and the use of steroids may be
important on an individual basis, but lose significance in
presence of other factors [67].
A critical element of supportive care is the manage-
ment of fluid and electrolyte requirements. Intravenous
fluid should be given to maintain urine output of 50 -
80 mL per hour with 0.5% NaCl supplemented with 20
mEq of KCl. Appropriate early and aggressive replace-
ment therapy is required in case of hyponatraemia,
hypokalaemia or hypophosphataemia which quite fre-
quently occur. Wounds should be treated conservatively,
without skin debridement which is often performed in
burn units, as blistered skin ac t sa san a t u r a lb i o l o g i c a l
dressing which likely favors re-epithelialization. Non-
adhesive wound dressings are used where required, and
topical sulfa containing medications should be avoided.
Drug Therapy
To date, a specific therapy for SJS/TEN that has shown
efficacy in controlled clinical trials unfortunately does
not exist. Several treatment modalities given in addition
to supportive care are reported in the literature and
these are discussed below.
- Systemic steroids were the standard treatment until
the early 1990’s, although no benefit has been proven in
controlled trials. In the absence of strong evidence of
efficacy, and due to the confusion resulting from the
numerous steroid treatment regimens reported (treat-
ment of short versus long duration, various dose regi-
mens), their use has become increasingly disputed.
A recent retrospective monocenter study suggests that a
short course “pulse” of high dose corticosteroids (dexa-
methasone) may be of benefit [68]. On the other hand,
a recent retrospective case-control study conducted by
Schneck et al. in France and Germany concluded that
corticosteroids did not show a significant effect on mor-
tality in comparison with supportive care only [69].
- Thalidomide, a medication with known anti-TNFa
activity that is immunomodulatory and anti-angiogenetic
has been evaluated for the treatment of TEN [70,71].
Unfortunately, in a double-blind, randomised, placebo-
controlled study higher mortality was observed in the
thalidomide-treated group suggesting that thalidomide is
detrimental in TEN.
- High-dose intravenous immunoglobulins. As a con-
sequence of the discovery of the anti-Fas potential of
pooled human intravenous immunoglobulins (IVIG) in
vitro [44], IVIG have been tested for the treatment of
Table 2 SCORTEN severity-of-illness score
SCORTEN Parameter Individual score SCORTEN (sum of individual scores) Predicted mortality (%)
Age > 40 years Yes = 1, No = 0 0-1 3.2
Malignancy Yes = 1, No = 0 2 12.1
Tachycardia (>120/min) Yes = 1, No = 0 3 35.8
Initial surface of epidermal detachment >10% Yes = 1, No = 0 4 58.3
Serum urea >10 mmol/l Yes = 1, No = 0 >5 90
Serum glucose >14 mmol/l Yes = 1, No = 0
Bicarbonate >20 mmol/l Yes = 1, No = 0
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controlled studies. To date, numerous case reports and
12 non-controlled clinical studies containing 10 or more
patients have analyzed the therapeutic effect of IVIG in
TEN (Table 3). All except one study [72], confirm the
known excellent tolerability and a low toxic potential of
IVIG when used with appropriate precaution in patients
with potential risk factors (renal insufficiency, cardiac
insufficiency, IgA deficiency, thrombo-embolic risk) [73].
Taken together, although each study has its potential
biases and the 12 studies are not directly comparable, 9
of the 12 studies suggest that there may be a benefit of
high-dose IVIG on the mortality associated with TEN
[44,69,72,74-82]. Analysis of studies published (Table 3),
suggests that total IVIG doses of more than 2 g/kg may
be of greater benefit than doses of 2 g/Kg or less. To
determine if a dose response relationship exists, Trent
et al. analyzed the published literature between 1992
and 2006, selected all studies performed in adults in
which the dose of IVIG administered was reported for
each patient, excluded cases appearing as duplicates in
separate publications where possible, and performed a
multivariate logistic regression analysis to evaluate mor-
tality and total IVIG dose after controlling for age and
affected body surface area [83]. Although this study has
limitations stated by the authors and including publica-
tion bias, heterogeneous diagnostic definitions and
methods of each study, as well as the exclusion of 2 stu-
dies owing to lack of individual IVIG dosing data, logis-
tic regression results showed that, with each 1 g/Kg
increase in IVIG dose, there was a 4.2-fold increase in
TEN patient survival, which was statistically significant.
Patients treated with high doses of IVIG had a signifi-
cantly lower mortality compared with those treated with
lower doses, and notably the mortality was zero percent
in the subset of 30 patients treated with more than 3 g/
kg total dose of IVIG. Given the favourable side-effect
p r o f i l eo fI V I Ga n dt h ed a t ae x i s t i n gt od a t e ,i nt h e
authors’ opinion early administration of high-dose
immunoglobulin (3 g/kg total dose given over 3-4 days)
should be considered alongside supportive care for the
treatment of toxic epidermal necrolysis, given
the absence of other validated specific therapeutic
alternatives.
The concomitant administration of corticosteroids or
immunosuppressive agents remains controversial. IVIG
has also been applied in a few children with SJS/TEN,
and two non-controlled studies suggest a possible bene-
fit [84,85].
- Ciclosporin (CsA). CsA, a calcineurin-inhibitor, is an
efficient drug in transplantation and autoimmune dis-
eases. Arevalo et al. have performed a study as a case
series with two treatment arms: CsA alone versus cyclo-
phosphamide in combination with corticosteroids.
Patients treated with CsA had significantly shorter time
to complete re-epithelialisation, and fewer patients with
multi-organ failure and death were observed [86].
A small case series with three TEN patients treated
initially with high-doses of intravenous dexamethasone
followed by CsA showed a stop in disease progression
within 72 h [87]. Other single case reports also reported
a positive effect of the use of CsA in TEN [88,89].
Recently, Valeyrie-Allanore L conducted an open,
phase II trial to determine the safety and possible bene-
fit of ciclosporin [90]. Twenty-nine patients were
included in the trial (10 SJS, 12 SJS-TEN overlap and
7 TEN), and 26 completed the treatment with CsA
administered orally (3 mg/kg/d for 10 days) and tapered
over a month. The prognostic score predicted 2.75
deaths and none occurred (p = 0.1), suggesting that,
although not statistically significant, ciclosporin may be
useful for the treatment of TEN.
- TNF antagonists. A new therapeutic approach tar-
geting the proinflammatory cytokine TNFa has been
Table 3 Summary of studies concerning IVIG for TEN
Trent Viard Prins Campione Al-Mutairi Shortt Tan Stella Rajaratnam Bachot Brown Schneck
2003 1998 2003 2003 2004 2004 2005 2007 2010 2003 2004 2008
(80) (44) (73) (76) (74) (78) (79) (82) (81) (72) (75) (69)
Study design Retro Prosp Retro Prosp Prosp Retro Retro Retro Retro Prosp Retro Retro
N/ N/ N/ N/ N/ N/ N/ Cont N/ N/ N/ Cont
Cont Cont Cont Cont Cont Cont Cont Cont Cont Cont
Patients 24 10 48 10 12 16 12 23 14 34 24 75
Detachm.(%) 44 39 45 49 58 “65”—— “ 44” 19 49 —
Total dose IVIG (g/kg) 4 3 3 2 2-5 2.8 2 — 3.3 2 1.6 1.9 (0.7-2.3)
Predicted mortality
(SCORTEN/APACHE*)
in %
33 —— 35 — 38 * — 35.8 36 24 28.6 25
Actual mortality in % 4 0 12 10 0 25 8 26 21 32 41.7 34
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Page 7 of 11proposed by Hunger et al. They treated one patient with
as i n g l ed o s eo ft h ec h i m e r i ca n t i - T N F a antibody
(infliximab 5 mg/kg) and reported that disease progres-
sion stopped within 24 hours followed by a complete
re-epithelialisation within 5 days [91]. Meiss et al. report
three cases with an overlap of acute generalized
exanthematous pustulosis and TEN and treatment
response to infliximab [92]. Administration of the solu-
ble TNFa Receptor Etanercept 25 mg on days 4 and 8
after onset of TEN in a single case resulted in cessation
of epidermal detachment within 24 hours but subse-
quent death of the patient. The published data is cur-
rently insufficient to draw a conclusion on the
therapeutic potential of TNF antagonists in TEN.
- Plasmapheresis/plasma exchange (PE). PE has also
been tried in SJS/TEN, but the current data does not
allow a conclusion as to the potential of this approach
to be drawn due to the small number of patients trea-
ted, the frequent confounding factors including different
or combined treatments, and other potential biases
[93-95]. Furthermore, a small single retrospective study
using PE by Furubacke et al., which compared their case
series with two published case series serving as controls,
showed no difference in terms of mortality [96].
- Cyclophosphamide (CPP). CPP has been studied in
small case series, either in combination with other treat-
ments such as CsA [86], in conjunction with high-dose
corticosteroids [97], or alone [98]. Although a beneficial
effect of CPP is suggested by the authors of these small
trials, larger studies are needed to clarify these prelimin-
ary results with a special attention to potential side
effects.
Treatment of sequelae
Due to the often combined involvement of the skin, eyes
and mucous membranes (oral, gastrointestinal, pulmon-
ary, genital, as well as urinary), the follow up and treat-
ment of sequelae should be interdisciplinary. Special
attention should be given to the prevention of ocular
complications. Early referral to an ophthalmologist is
mandatory for assessment of the extent of eye involve-
ment and prompt treatment with topical steroids. Visual
outcome is reported to be significantly better in patients
who receive specific ophtalmological treatment during
the first week of disease [23]. Some of the ocular com-
plications have an inflammatory background and have
to be treated occasionally with ophthalmic steroids and/
or extensive lubrication of the eye [26] in order to pre-
vent progression leading ultimately to the need for cor-
neal transplantation. A small single retrospective study
with IVIG showed no significant effect on ocular com-
plications in frequency and severity, but the power of
the study was weak [99]. The benefit of local antibiotic
treatment (ointments) is not clear. Yip et al. have
reported that the use of local antibiotic treatment leads
to more late complications, including, for example, dry-
ness of the eyes [24]. Hypopharyngeal stenosis combined
with dysphagia and oesophageal strictures are long-term
complications which are difficult to treat [100,101] and
may require laryngectomy.
Allergological testing
A detailed drug history is very important when striving
to identify the culprit drug in SJS/TEN. In some cases
several drugs are possible candidates and allergological
testing can be of help in identifying the most likely can-
didate. In principle, the severity of SJS and TEN does
not allow re-challenge and intradermal testing with the
culprit drugs due to the feared risk of re-inducing a sec-
ond episode of SJS/TEN, although two case reports
describe intradermal testing without triggering of a sec-
ond episode of TEN [102,103]. Induction of SJS/TEN
has, however, been documented following local eye
treatment [104,105].
Patch-testing is an investigational option, but not a rou-
tine diagnostic option at the moment. Data from Wolk-
enstein et al. has shown that low sensitivity is a problem
with patch testing in SJS/TEN, as only two of 22 tested
patients had a relevant positive patch test [106].
Currently the focus of allergological testing lies more
on ex vivo/in vitro tests. The lymphocyte transformation
test (LTT), that measures the proliferation of T cells to
ad r u gin vitro has shown a sensitivity of 60-70% for
patients allergic to beta-lactam antibiotics [107]. Unfor-
tunately the sensitivity of the LTT is still very low in
SJS/TEN even if performed within one week after onset
of the disease [108].
Another recently reported approach looks for up-regu-
lation of CD69 on T-lymphocytes two days after lym-
phocyte stimulation in vitro as a sign of drug
hypersensitivity [109]. Novel in vitro methods to help
identify culprit drug in SJS/TEN are still needed [110].
Prognosis
SJS and TEN are severe and life-threatening. The aver-
age reported mortality rate of SJS is 1-5%, and of TEN
is 25-35%; it can be even higher in elderly patients and
those with a large surface area of epidermal detachment
[64]. In order to standardize the evaluation of risk and
p r o g n o s i si np a t i e n t sw i t hS JS/TEN, different scoring
systems have been proposed. The SCORTEN is now the
most widely used scoring system and evaluates the fol-
lowing parameters: age, malignancy, tachycardia, initial
body surface area of epidermal detachment, serum urea,
serum glucose, and bicarbonate (Table 2) [111]. Yun
et al. reported recently that lactate dehydrogenase
(LDH) may be an additional useful parameter in the
evaluation of disease severity [112].
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Page 8 of 11More than 50% of patients surviving TEN suffer from
long-term sequelae of the disease. These include sym-
blepharon, conjunctival synechiae, entropion, ingrowth
of eyelashes, cutaneous scarring, irregular pigmentation,
eruptive nevi, and persistent erosions of the mucous
membranes, phimosis, vaginal synechiae, nail dystrophy,
and diffuse hair loss.
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